Antigen-specific immune tolerance could redefine autoimmune disease treatment by precisely retraining the immune system rather than broadly suppressing it.
- Are Biopharma Companies Outsourcing Their Ability To Think?
- June 2026 — CDMO Opportunities And Threats Report
- The Decision Rights Matrix: Making Sponsor-CDMO Governance Enforceable
- Defining Quality In A Sponsor-Owned QTPP Before The CDMO Even Starts
- ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive Malignancies
- Reshoring Pressure Meets Manufacturing Reality
- CDMO Live Europe 2026: Partnerships For An Uncertain World
- Resilience, Risk, And Relationships: CDMO Live Europe 2026 Report
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Lightning-Link® Conjugation Kits: Consistent Performance On A Broad Scale
Learn about labeling technology offering a transformative solution through direct antibody labeling without the need for post-conjugation purification, thereby mitigating antibody loss and ensuring reproducible results.
-
The Need For Adaptive Distribution Partners For Cell And Gene Therapies
Optimize your commercial strategy by exploring how adaptive distribution models navigate reimbursement challenges and improve patient access. Partner early to align workflows and ensure operational success.
-
Automated Testing For Compound Toxicity Effects
Explore how anti-cancer drugs' toxic effects on intestinal cells limit dosages as well as how 3D organoids and assay automation can enhance drug development by improving testing processes.
-
Collaborative Variability Reduction In Cell Culture Media
Variability reduction programs improve biomanufacturing by controlling raw‑material complexity, optimizing critical attributes, and boosting productivity through data‑driven partnerships.
-
The Complete Flow Cytometry Guide
This guide covers the fundamentals of flow cytometry, aiming to help you better understand how it works, when it is most valuable, and how to conduct an experiment.
-
Improve mAb Purification Process Efficiency With Mixed-Mode Resins
Does your monoclonal antibody (mAb) purification process have three steps? Are you trying to improve purity, yield, and process economics?
-
Building A High-Quality IND From Scratch With Strategic Gap Analysis
A biotech sponsor lacking in-house regulatory expertise engaged a partner to obtain strategic regulatory review, medical writing, project management, and electronic publishing (eCTD).
-
Annex 1: Sterile Fill/Finish For Early Phase Clinical Supplies
Meeting stringent requirements for sterile fill/finish operations hinges on robust contamination control strategies, advanced isolator technology, and rigorous integrity testing to ensure patient safety.
-
Digital Solutions Enhance Pharmaceutical Manufacturing Performance
Personalised therapies and advanced technologies are reshaping manufacturing. Explore how intelligent automation can improve flexibility, strengthen data integrity, and accelerate production.
-
Cell Type Setting Considerations For Counting Clumpy Cells
Cell clumping can dramatically affect counting accuracy. Learn how declustering, mixing, and aspiration settings influence cell density measurements and help generate more reliable viability.
NEWSLETTER ARCHIVE
- 08.14.26 -- The Fast Track to GMP Compliance
- 08.14.26 -- The Missing Layer: Why CAR-T Needs AI As Its Connective Tissue
- 08.13.26 -- New Resources: MSC Manufacturing, Expansion, and Scale-Up Technologies
- 08.13.26 -- Building A Self-Driving Lab For LNP Development
- 08.12.26 -- Better Data For Cell & Gene Therapy Development
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
- Solving Vector Yield Challenges Starts Long Before Manufacturing
- Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors
- FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy
- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections